InflaRx presented kidney data. InflaRx stock stood at a USD 254.9 million market value.

Published on 10/29/2026 at 13:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Izicopan cut kidney injury markers in two hamster models on October 22, 2026. InflaRx stock costs EUR 1.55 on October 29, 2026.

Pipeline data and reporting date

On October 22, 2026, izicopan was tested at 100 mg/kg in an acute kidney injury model.
InflaRx will report third-quarter 2026 results on November 3, 2026.
Cash and cash equivalents stood at USD 146.6 million at the end of the second quarter of 2026.

IFRX, NL0012661870, Illustration mit AI erstellt.

InflaRx (ISIN NL0012661870) stood at a USD 254.9 million market value as of October 28, 2026. On October 22, 2026, the biopharmaceutical company presented new izicopan data from two kidney injury models, according to GlobeNewswire.

Kidney data frame izicopan

InflaRx evaluated izicopan in an acute kidney injury model and a progressive kidney injury and fibrosis model involving hamsters. In the first model, a single oral dose of 100 mg/kg reduced creatinine and blood urea nitrogen compared with vehicle controls, with both results reaching p less than 0.001, Times Argus reported on October 22, 2026.

The second model used daily treatment for 14 days and produced lower blood urea nitrogen and better tissue-injury scores. The observed fibrosis trend was not statistically significant, making the kidney findings a development signal rather than clinical proof.

Three dated pipeline steps

On October 1, 2026, InflaRx appointed Gabriela Alperovich as senior vice president and global head of clinical development, according to MarketScreener. On October 22, the company presented the two-model izicopan data. On October 27, it announced its next results and investor-event schedule through GlobeNewswire.

What follows on November 3?

InflaRx will report third-quarter 2026 financial and operating results before the market opens on November 3, 2026. The same date brings a virtual Capital Markets Event focused on ANCA-associated vasculitis, izicopan chemistry and the anticipated clinical program, according to GlobeNewswire.

For financial context, InflaRx reported USD 146.6 million in cash and cash equivalents at June 30, 2026. Second-quarter net income was a loss of USD 10.6 million, while operating cash flow was negative USD 2.6 million. These figures leave the November update with two tests: pipeline execution and capital use.

The next trading reference

The stock was trading at EUR 1.55 at Lang & Schwarz on October 29, 2026 at 1:03 p.m. CET. The quote is an intraday reference for German investors while the Nasdaq-listed company prepares its next operational update.

The further course of trading is shown by the continuously updated real-time quote of InflaRx stock.